Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial

BACKGROUND: Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for patients with resectable pancreatic cancer. The main concern regarding adjuvant chemotherapy is that only half of patients actually rece...

Descripción completa

Detalles Bibliográficos
Autores principales: van Dam, J. L., Verkolf, E. M. M., Dekker, E. N., Bonsing, B. A., Bratlie, S. O., Brosens, L. A. A., Busch, O. R., van Driel, L. M. J. W., van Eijck, C. H. J., Feshtali, S., Ghorbani, P., de Groot, D. J. A., de Groot, J. W. B., Haberkorn, B. C. M., de Hingh, I. H., van der Holt, B., Karsten, T. M., van der Kolk, M. B., Labori, K. J., Liem, M. S. L., Loosveld, O. J. L., Molenaar, I. Q., Polée, M. B., van Santvoort, H. C., de Vos – Geelen, J., Wumkes, M. L., van Tienhoven, G., Homs, M. Y. V., Besselink, M. G., Wilmink, J. W., Groot Koerkamp, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405377/
https://www.ncbi.nlm.nih.gov/pubmed/37550634
http://dx.doi.org/10.1186/s12885-023-11141-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405377/
https://www.ncbi.nlm.nih.gov/pubmed/37550634
http://dx.doi.org/10.1186/s12885-023-11141-5

Ejemplares similares